Bio Rad Labs Cl B (BIO.B) 151.40 $BIO.B Bio-Rad
Post# of 273332
Posted On: 09/07/2016 9:30:33 PM
Bio Rad Labs Cl B (BIO.
151.40 $BIO.B
Bio-Rad Reports Second-Quarter 2016 Financial Results
Marketwire Canada - Wed Aug 03, 3:18PM CDT
HERCULES, CA--(Marketwired - Aug 3, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 159.32 (+7.66), ILMN: 169.58 (-0.60), BIO.B: 151.40 (unch)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 161.64 (+1.29), BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Reports Third-Quarter 2015 Financial Results
Marketwired - Tue Nov 03, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad to Report Third-Quarter 2015 Financial Results Tuesday, November 3, 2015
Marketwired - Mon Oct 19, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2015 on Tuesday, November 3, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
Marketwired - Mon Aug 03, 7:30AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Announces U.S. FDA Pre-Market Approval for the BioPlex 2200 HIV Ag-Ab Assay, a Novel Next Generation HIV Diagnostic Test
Marketwired - Tue Jul 28, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration pre-market approval to offer its BioPlex(R) 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
151.40 $BIO.B Bio-Rad Reports Second-Quarter 2016 Financial Results
Marketwire Canada - Wed Aug 03, 3:18PM CDT
HERCULES, CA--(Marketwired - Aug 3, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA). BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO.
on Thursday reported first-quarter profit of $12.3 million. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016. BIO: 159.32 (+7.66), ILMN: 169.58 (-0.60), BIO.B: 151.40 (unch)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety. IBM: 161.64 (+1.29), BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators." BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Reports Third-Quarter 2015 Financial Results
Marketwired - Tue Nov 03, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad to Report Third-Quarter 2015 Financial Results Tuesday, November 3, 2015
Marketwired - Mon Oct 19, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2015 on Tuesday, November 3, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
Marketwired - Mon Aug 03, 7:30AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
Bio-Rad Announces U.S. FDA Pre-Market Approval for the BioPlex 2200 HIV Ag-Ab Assay, a Novel Next Generation HIV Diagnostic Test
Marketwired - Tue Jul 28, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration pre-market approval to offer its BioPlex(R) 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test. BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)
(0)
(0)